Active	Status	Sponsor type	Region	Phase	Filter
18 Active 7 Inactive 25 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes: « June » « 2025 » M T W T F S S 26 27 28 29 30 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4 5 6   - « June » « 2025 » M T W T F S S 26 27 28 29 30 31 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 1 2 3 4 5 6   Show only changed items Enrollment:

Advanced Filters

8 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Grignani, Giovanni
FIBROSARC, NCT04650984 / 2016-003239-38: A Study Comparing the Efficacy of L19TNF+Doxorubicin vs Doxorubicin Alone as First-line Therapy in Patients With Advanced or Metastatic Soft Tissue Sarcoma	Recruiting	3	102	Europe	Onfekafusp alfa, L19TNF, Doxorubicin	Philogen S.p.A.	Soft Tissue Sarcoma	12/25	12/25
REGISTRI, NCT02638766 / 2015-001048-12: Single Agent Regorafenib in First-line for Metastatic/Unresectable KIT/PDGFR Wild Type GIST	Completed	2	15	Europe	regorafenib, Stivarga	Grupo Espanol de Investigacion en Sarcomas, Bayer	Gastrointestinal Stromal Tumors	08/21	08/21
FLASH, NCT04733183 / 2018-004104-19: Efficacy and Safety of L19TNF in Previously Treated Patients with Advanced Stage or Metastatic Soft-tissue Sarcoma	Active, not recruiting	2	98	Europe	Dacarbazine, DTIC, onfekafusp alfa, L19TNF	Philogen S.p.A., Philogen S.p.A.,	Soft Tissue Sarcoma	12/25	12/25
ChonDRAgon, NCT04950075: Study of INBRX-109 in Conventional Chondrosarcoma	Recruiting	2	201	Europe, US, RoW	INBRX-109, Placebo	Inhibrx Biosciences, Inc	Conventional Chondrosarcoma	09/25	12/26
ERASING, NCT03840772 / 2018-004571-12: Eribulin in Advanced Solitary Fibrous Tumor	Completed	2	16	Europe	Eribulin, Intervention under investigation	Italian Sarcoma Group, Eisai Inc.	Solitary Fibrous Tumor	09/24	09/24
ISG-MCS, NCT04305548 / 2019-003733-41: Study on Trabectedin in Advanced Rearranged Mesenchymal Chondrosarcoma	Recruiting	2	16	Europe	Trabectedin	Italian Sarcoma Group, PharmaMar	Mesenchymal Chondrosarcoma	08/25	12/25
TOMAS2, NCT03838744 / 2018-004497-10: Randomized Trial in Advanced, Metastatic or Unresectable Soft Tissue Sarcoma After Failure of Standard Treatments.	Completed	2	130	Europe	Standard arm: Trabectedin in monotherapy, Trabectedin arm, Experimental arm: Trabectedin + Olaparib, Trabectedin+ Olaparib arm	Italian Sarcoma Group, PharmaMar, AstraZeneca	Advanced Soft Tissue Sarcoma	11/24	11/24
Morabito, Simone
ChonDRAgon, NCT04950075: Study of INBRX-109 in Conventional Chondrosarcoma	Recruiting	2	201	Europe, US, RoW	INBRX-109, Placebo	Inhibrx Biosciences, Inc	Conventional Chondrosarcoma	09/25	12/26

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Grignani, Giovanni
FIBROSARC, NCT04650984 / 2016-003239-38: A Study Comparing the Efficacy of L19TNF+Doxorubicin vs Doxorubicin Alone as First-line Therapy in Patients With Advanced or Metastatic Soft Tissue Sarcoma	Recruiting	3	102	Europe	Onfekafusp alfa, L19TNF, Doxorubicin	Philogen S.p.A.	Soft Tissue Sarcoma	12/25	12/25
REGISTRI, NCT02638766 / 2015-001048-12: Single Agent Regorafenib in First-line for Metastatic/Unresectable KIT/PDGFR Wild Type GIST	Completed	2	15	Europe	regorafenib, Stivarga	Grupo Espanol de Investigacion en Sarcomas, Bayer	Gastrointestinal Stromal Tumors	08/21	08/21
FLASH, NCT04733183 / 2018-004104-19: Efficacy and Safety of L19TNF in Previously Treated Patients with Advanced Stage or Metastatic Soft-tissue Sarcoma	Active, not recruiting	2	98	Europe	Dacarbazine, DTIC, onfekafusp alfa, L19TNF	Philogen S.p.A., Philogen S.p.A.,	Soft Tissue Sarcoma	12/25	12/25
ChonDRAgon, NCT04950075: Study of INBRX-109 in Conventional Chondrosarcoma	Recruiting	2	201	Europe, US, RoW	INBRX-109, Placebo	Inhibrx Biosciences, Inc	Conventional Chondrosarcoma	09/25	12/26
ERASING, NCT03840772 / 2018-004571-12: Eribulin in Advanced Solitary Fibrous Tumor	Completed	2	16	Europe	Eribulin, Intervention under investigation	Italian Sarcoma Group, Eisai Inc.	Solitary Fibrous Tumor	09/24	09/24
ISG-MCS, NCT04305548 / 2019-003733-41: Study on Trabectedin in Advanced Rearranged Mesenchymal Chondrosarcoma	Recruiting	2	16	Europe	Trabectedin	Italian Sarcoma Group, PharmaMar	Mesenchymal Chondrosarcoma	08/25	12/25
TOMAS2, NCT03838744 / 2018-004497-10: Randomized Trial in Advanced, Metastatic or Unresectable Soft Tissue Sarcoma After Failure of Standard Treatments.	Completed	2	130	Europe	Standard arm: Trabectedin in monotherapy, Trabectedin arm, Experimental arm: Trabectedin + Olaparib, Trabectedin+ Olaparib arm	Italian Sarcoma Group, PharmaMar, AstraZeneca	Advanced Soft Tissue Sarcoma	11/24	11/24
Morabito, Simone
ChonDRAgon, NCT04950075: Study of INBRX-109 in Conventional Chondrosarcoma	Recruiting	2	201	Europe, US, RoW	INBRX-109, Placebo	Inhibrx Biosciences, Inc	Conventional Chondrosarcoma	09/25	12/26